Startseite
Reels
Gruppen
Seiten
Mehr sehen
Gruppen Seiten Veranstaltungen Blogs Spendenaufruf
Anmelden Registrieren
Nachtmodus
Autologous vs. Allogeneic: The CAR T Manufacturing Race
The promise of CAR T therapy is constrained by a manufacturing challenge: creating personalized treatments at scale is complex, time-consuming, and expensive. Autologous therapy—using the patient's own cells—requires a bespoke manufacturing process for each patient, with vein-to-vein times that can delay treatment. Allogeneic therapy—using donor cells—offers the...
0 Kommentare ·0 Geteilt ·21 Ansichten ·0 Bewertungen
Bitte loggen Sie sich ein, um liken, teilen und zu kommentieren!